

REMARKS

Status of the claims

Claims 1, 2, 8-23, 26, 32, 40, 50, 51, 58, 64, 71, 72, and 78-80 are pending and claims 8 and 78-80 are under consideration in this application, claims 3-7, 24, 25, 27-31, 33-39, 41-49, 52-57, 59-63, 65-70, and 73-77 having been cancelled and claims 1, 2, 9-23, 26, 32, 40, 50, 51, 58, 64, 71, and 72 having been withdrawn for allegedly being drawn to separate inventions. All the claims under consideration stand rejected.

Claim 8 is amended. Claims 78 and 80 are cancelled and claim 79 is amended to be dependent on claim 8.

No new matter is added by any of the amendments made herein.

After entry of the amendments made herein, claims 1, 2, 8-23, 26, 32, 40, 50, 51, 58, 64, 71, 72, and 79 will be pending and claims 8 and 79 will be under consideration in this application.

Election/Restriction

Applicants thank the Examiner for entering and examining amended claim 8 and new claims 78-80.

35 U.S.C. § 112, first paragraph, rejections

(a) Claims 78 and 80 stand rejected on the ground that they allegedly contain subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention.

From the comments on page 2, line 19, to page 3, line 6, of the Office Action, Applicants understand the Examiner's position to be that embodiments of the claimed methods in which the test and control cells are stromal cells and in which cathepsin K (CTSK) is expressed at a different level in invasive breast cancer cells from ductal carcinoma in situ (DCIS) cells are not supported by the specification.

While disagreeing with this position, in order to expedite prosecution of the instant application, Applicants have cancelled claims 78 and 80 and have amended claim 79 to be dependent on claim 8. In light of these amendments, Applicants submit that the rejection of claims 78 and 80 is moot.

(b) Claims 8 and 78-80 stand rejected as allegedly containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. Applicants respectfully traverse the rejection.

The rejection is moot in regard to claims 78 and 80 which have been cancelled.

While not agreeing with the objections on page 5, line 17, to page 6, line 3, of the Office Action, Applicants submits that they are moot in view of the limiting of claim 8 to methods using human breast tissue.

From the comments on page 3, line 7, to page 6, line 16, of the Office Action, Applicants understand the Examiner's position to be that the specification does not provide enablement for the methods of the instant claims in which the CTSK gene is expressed at a different level in DCIS and invasive breast cancer. Applicants respectfully disagree with this position.

Thus, for example, at page 19, lines 10-14, of the instant specification, it is stated that:

[T]he invention features diagnostic assays. Such assays are based on the findings that: . . breast cancers of various grades and/or stages differ from each other in terms of the patterns of genes they express and in the levels at which they express them.

Moreover, on page 22, line 30, to page 23, line 7, of the instant specification, it is stated that:

a test expression profile of a gene in a test cell (or tissue) can be compared to control expression profiles of control cells (or tissues) previously established to be of defined category (e.g., DCIS grade, breast cancer stage, or state of differentiation). The category of the (*sic*) test cell (or tissue) will be that of the control cell (or tissue) whose expression profile the test cell's (or tissue's) expression profile most closely resembles. These expression profile comparison assays can be used to compare any of the normal breast tissue with any stage and/or grade of breast cancer recited herein and/or to compare

between breast cancer grades and stages. The genes analyzed can be any of those listed in Tables 1-16 and the number of genes analyzed can be any number, i.e. one or more.

Applicants submit that one skilled in the art reading the text quoted above would have understood that the CTSK gene (listed in Table 16) is a gene that could be differentially expressed in DCIS and invasive breast cancer. In view of this teaching and the disclosure on page 123, lines 18-25, that CTSK is expressed in both DCIS and invasive cancer but, importantly, not in cells from normal breast tissue, the artisan would have reasonably considered that the CTSK gene would indeed be differentially expressed in DCIS and invasive breast cancer. Where a gene is expressed in cancer cells of various stages and grades but not in normal cells, a strong possibility is that the expression of the gene increases with the degree of advancement of the cancer. Furthermore, he or she would have been further persuaded by his own knowledge and the disclosure of the present application that many genes that are expressed in DCIS and invasive breast cancer are expressed at different levels in the two grades of breast cancer (see the instant specification at, e.g.: page 2, lines 14-20; page 70, lines 14-25 and the table (Table 4) this text describes; page 74, lines 22-24; page 75, lines 14-23; and page 115, lines 3-10).

Moreover, given the entirely straight-forward methods of testing for relative levels of gene expression in different tissues (e.g., those described in the present application) with which he or she would have been very familiar, the small few genes listed in the text on page 123, lines 18-20, of the application (PDGF, PDGFRBL, CTSK, and CXCL12), and the high value of a positive result, the skilled artisan would have proceeded with the appropriate routine experimentation to test for the relevant differential expression. As shown by a post-filing publication by, *inter alia*, one of the present inventors (Kleer et al. (2008) Clin. Cancer Res. 14:5357-5367; copy enclosed as Exhibit A), the artisan would have been correct in his or her reasonable belief, at the original filing date of the instant application, in the differential expression of the CTSK gene by DCIS and invasive breast cancer cells.

Applicant : Polyak et al.  
Serial No. : 10/550,162  
Filed : August 29, 2006  
Page : 13 of 14

Attorney's Docket No.: 00530-0116US1 / DFCI 853.05

In light of the above considerations, Applicants respectfully request the rejections under 35 U.S.C. § 112, first paragraph, be withdrawn.

CONCLUSION

In summary, for the reasons set forth above, Applicants maintain that the pending claims patentably define the invention. Applicants request that the Examiner reconsider the rejections as set forth in the Office Action, and permit the pending claims to pass to allowance.

If the Examiner would like to discuss any of the issues raised in the Office Action, Applicants' undersigned representative can be reached at the telephone number listed above

Enclosed herewith is a request for an automatic extension of time. Please apply the charge for the extension of time and any other charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No. 00530-0116US1.

Respectfully submitted,

Date: November 17, 2009

/Stuart Macphail/

Stuart Macphail, Ph.D., J.D.  
Reg. No. 44,217

Fish & Richardson P.C.  
601 Lexington Avenue  
Floor 52  
New York, NY 10022  
Telephone: (212) 765-5070  
Facsimile: (877) 769-7945

# **EXHIBIT A**

## Epithelial and Stromal Cathepsin K and CXCL14 Expression in Breast Tumor Progression

Celina G. Kleer,<sup>1</sup> Noga Bloushtain-Qimron,<sup>2,3</sup> Yu-Hui Chen,<sup>3</sup> Daniel Carrasco,<sup>2</sup> Min Hu,<sup>2,4</sup> Jun Yao,<sup>2,4</sup> Stine-Kathrin Kraef,<sup>4,6</sup> Laura C. Collins,<sup>4,6</sup> Michael S. Sabel,<sup>1</sup> Pedram Argani,<sup>7</sup> Rebecca Gelman,<sup>3,4,5</sup> Stuart J. Schmitt,<sup>4,6</sup> Ian E. Krop,<sup>2,4</sup> and Kornelia Polyak,<sup>2,4</sup>

### Abstract

**Purpose:** To evaluate the expression of cathepsin K (CTSK) and CXCL14 in stromal and epithelial cells in human breast tumor progression.

**Experimental Design:** We did immunohistochemical analyses of CTSK and CXCL14 expression in normal breast tissue, biopsy sites, benign lesions, ductal carcinoma *in situ*, and invasive breast tumors of different stages. Expression patterns were related to histopathologic characteristics of the tumors and clinical outcome. The effect of CTSK+ breast stromal fibroblasts on CTSK- breast cancer cells was assessed in coculture.

**Results:** Epithelial expression of CTSK was rarely detected in any of the tissue samples analyzed, whereas CXCL14-positive epithelial cells were found in all tissue types. The expression of CXCL14 was not associated with any tumor or patient characteristics analyzed. Stromal CTSK expression was significantly higher in invasive compared with *in situ* carcinomas, and in one of the two datasets analyzed, it correlated with higher tumor stage. Among all samples examined, the highest stromal CTSK levels were detected in biopsy sites. Neither epithelial nor stromal expression of CTSK was significantly associated with recurrence-free or overall survival. Coculture of CTSK+ fibroblasts enhanced the invasion of CTSK- breast tumor epithelial cells and this was blocked by CTSK inhibitors.

**Conclusions:** CTSK may function as a paracrine factor in breast tumorigenesis. CTSK+ fibroblasts may play a role in tumor progression by promoting the invasiveness of tumor epithelial cells. The possibility that CTSK inhibitors may have a clinical role in decreasing the risk of tumor progression merits further investigation.

**Authors' Affiliations:** <sup>1</sup>Departments of Pathology and Surgery, University of Michigan Cancer Center, Ann Arbor, Michigan; <sup>2</sup>Departments of <sup>3</sup>Medical Oncology and <sup>4</sup>Biostatistics and Computational Biology, Dana-Farber Cancer Institute; <sup>5</sup>Harvard Medical School; <sup>6</sup>Harvard School of Public Health; <sup>7</sup>Department of Pathology, Beth-Israel Deaconess Medical Center, Boston, Massachusetts; <sup>8</sup>Johns Hopkins University School of Medicine, Baltimore, Maryland; and <sup>9</sup>Ben Gurion University of the Negev, Beer Sheva, Israel  
Received 3/20/08; revised 5/20/08; accepted 5/21/08.

**Grant support:** National Cancer Institute SPORE in Breast Cancer grant CA83939 and Dana-Farber/Harvard Cancer Center grant CA006516 (S.J. Schmitt); Department of Defense grant W81XWH-04-1-0452, National Cancer Institute grant CA16232, and American Cancer Society grant RSG-05-184-01-MGO (K. Polyak); Susan G. Komen Foundation fellowship (M. Hu); Department of Defense grant BC030054 (P. Argani); and National Cancer Institute grants CA107469 and CA090876 (C.G. Kleer).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

**Note:** Supplementary data for this article are available at Clinical Cancer Research Online (<http://clincan.acs.org/journals/ccr>).

C.G. Kleer and N. Bloushtain-Qimron, equal contribution.

Current address for S.-K. Kraef: Anapath Diagnostics, Cheyenne, WY.

**Requests for reprints:** Kornelia Polyak, Dana-Farber Cancer Institute, 44 Binney Street D740C, Boston, MA 02115. Phone: 617-632-2106; Fax: 617-582-8490. E-mail: [Kornelia.Polyak@dfci.harvard.edu](mailto:Kornelia.Polyak@dfci.harvard.edu).

© 2008 American Association for Cancer Research.

doi:10.1158/1078-0432.CCR-08-0732

The importance of epithelial-stromal cell interactions in breast tumorigenesis has increasingly been recognized (1–3). Cells composing the microenvironment have been shown to promote tumor growth, invasion, angiogenesis, and metastatic capacity in various model systems (1–3). To investigate molecular alterations that occur in cells composing the microenvironment during tumor progression, we previously characterized the gene expression, DNA methylation, and genetic profiles of various cell types isolated from normal breast tissue and from ductal carcinoma *in situ* (DCIS) and invasive tumors (4, 5). Based on these analyses, we found dramatic gene expression and DNA methylation changes in all cell types during breast tumor progression, whereas clonally selected genetic alterations were restricted to tumor epithelial cells. Many of the genes differentially expressed between normal and DCIS-associated myoepithelial cells and highly expressed in stromal myofibroblasts encoded proteases, protease inhibitors, extracellular matrix proteins, and chemokines. The up-regulation of these genes in tumor-associated myoepithelial and stromal cells suggested the activation of aberrant paracrine interactions and perturbed balance in extracellular matrix degrading protease activity resembling a wound-healing response (6). Cathepsins and their inhibitors (cystatins) and the CXCL14 chemokine were among the most highly overexpressed genes in

## Translational Relevance

The regulation of *in situ* to invasive carcinoma transition is a poorly understood yet critical important step of breast tumorigenesis. Increasing evidence suggests that during tumorigenesis abnormalities occur not only in breast cancer cells but also in the surrounding stromal cells. A tumor is an abnormal organ with its own blood vessels, inflammatory, and supportive cells, and effective interaction among these cells is essential for the growth and maintenance of the tumor. Unlike cancer cells, stromal cells are thought to be genetically stable and therefore are less likely to develop resistance to cancer therapy. Thus, therapeutic targeting of stromal cells may be beneficial for cancer treatment. In this article, we provide evidence that stromal expression of CTSK may play a role in breast tumor progression. Specifically, CTSK may act as a paracrine factor to promote the progression of DCIS to invasive tumors. Thus, inhibition of CTSK activity may decrease the risk of breast tumor progression and should be explored further in clinical trials.

DCIS-associated myoepithelial cells and in myofibroblasts. Cathepsins and chemokines have been implicated in tumor progression and the feasibility of their therapeutic targeting is currently being explored for cancer treatment.

Cathepsins are lysosomal cysteine proteases that have been implicated in tissue remodeling and angiogenesis and in the processing of certain hormones, transcription factors, and immunogens (7, 8). The human cathepsin gene family is composed of 11 members [cathepsins B (CTSB), C, H, F (CTSF), K (CTSK), L (CTSL), O, S, V, W, and X/Z] each with their unique as well as overlapping function as revealed by the phenotype of mutant mice deficient for individual genes or their combination. The activity of cathepsins is regulated at multiple levels including control of gene expression, protein activation, and association with cystatins that are potent protease inhibitors (9). Recent studies implicated several cathepsins in tumor progression using an animal model of multistage carcinogenesis (8, 10). Inhibition of cathepsin activity appears to be a promising therapeutic approach for the treatment of metastatic disease and inhibition of tumor progression (11).

CTSK is highly expressed in osteoclasts and plays an essential role in bone remodeling as shown by the osteopetrotic phenotype of the CTSK<sup>-/-</sup> mouse (12). Related to this, CTSK inhibitors have successfully been used in the clinic for the treatment of osteopetrosis-associated bone loss and preclinical studies have shown their effectiveness in reducing bone metastases of breast carcinomas (13). Besides osteoclasts, CTSK is also highly expressed in a subset of leukocytes and in synovial fibroblasts in rheumatoid and osteoarthritis (14, 15). Previous studies analyzing the expression of CTSK in human breast tumors described expression only in bone metastases (16). However, in our previous studies, we found high expression of CTSK in breast tumor-associated myoepithelial cells and myofibroblasts, suggesting that CTSK may play a paracrine role in tumorigenesis (4).

The CXCL14 (BRAK) is a chemokine with unknown function that was initially identified as a chemokine highly expressed

in the kidney and breast (17). Its receptor is still unknown, but CXCL14 has been shown to be a chemoattractant for monocytes, B cells, and dendritic cells and has also been implicated to play a role in the regulation of tumor cell growth, angiogenesis, and activation of NK cells (18–22). The phenotype of the CXCL14-deficient mice revealed no immunologic or other gross anatomic abnormalities, although homozygous-null mice were born at lower than expected frequency from heterozygous crosses (23). However, CXCL14<sup>-/-</sup> mice were resistant to high fat diet-induced obesity and diabetes (24). Associated with its potential role in obesity, CXCL14 was also shown to be induced by growth hormone, insulin-like growth factor, and insulin in hepatocytes and to enhance insulin-independent glucose uptake in adipocytes (25). Whether CXCL14 is induced by the same growth factors in other cell types, such as breast tumor epithelial cells, has not been investigated. In our previous study, we found high expression of CXCL14 in DCIS-associated myoepithelial cells as well as in the epithelial cells of a subset of breast carcinomas (4). Thus, CXCL14 may contribute to breast tumorigenesis via multiple different mechanisms including both autocrine and paracrine effects.

To investigate the potential roles of CTSK and CXCL14 in breast tumor progression, we analyzed their expression in stromal and epithelial cells in a variety of normal and diseased human breast tissue samples including benign disorders and biopsy sites and in *in situ*, invasive, and metastatic breast carcinomas. The relationship between the expression of CTSK and normal and diseased human breast tissue specimens was examined in two data sets, one of which also had data on CXCL14 expression. The association of recurrence-free survival (RFS) and CTSK expression and other tumor and patients covariates was examined in another data set.

## Materials and Methods

**Tissue specimens and cell cultures.** Human tissue specimens made into tissue microarrays were provided by Petagen, purchased from Imgenex, or constructed at the University of Michigan Cancer Center (UMCC) and at the Beth-Israel Deaconess Medical Center (BIDMC) as described previously (26). Each of the four sources of tissue microarrays was associated with different data items. The BIDMC provided normal breast tissue of two types, benign breast tissue of three types, and biopsy site tissue; all these tissue types had CTSK expression measured in the stroma. The BIDMC also provided specimens with atypical ductal hyperplasia (ADH), low- to intermediate grade DCIS, high-grade DCIS, infiltrating ductal carcinoma, and radial scar/complex sclerosing lesions; all these tissue types had CTSK expression and CXCL14 expression measured in both stromal and epithelial cells. All of the tissue microarrays from BIDMC are referred to as the BIDMC data set. Tissue microarrays provided by Petagen and purchased from Imgenex were made from tissue from Korean patients with invasive breast cancer (some ductal and some lobular). This data set (referred to as the Korean data set) included data on some patient and tumor characteristics, data on CTSK expression in stroma from all patients used in the analysis, and data on CXCL14 for about half of the patients (with 97% of the CXCL14 expression data being from stroma and 3% of the CXCL14 expression data being from epithelium). The UMCC provided tissue microarrays were made from tissue from stage I, II, or III invasive breast cancer; all the specimens used in analysis had CTSK expression measured in both stroma and epithelium. This data set (referred to as the UMCC data set) included data on some patient and tumor characteristics (many in common with the Korean data set) as well as data on relapse-free survival and overall survival. Expression of CTSK

**Table 1.** Summary of CTSK and CXCL14 expression in all tissue types

## (A) Overall distribution of CTSK and CXCL14 in stroma and in epithelium by tissue types

Tissue types	CTSK in stroma				CTSK in epithelium				CXCL14 in stroma				CXCL14 in epithelium			
	-	+	++	+++	-	+	++	+++	-	+	++	+++	-	+	++	+++
Benign (NP)	5	8	4	3	-	-	-	-	-	-	-	-	-	-	-	-
Benign (SA)	5	7	5	3	-	-	-	-	-	-	-	-	-	-	-	-
Benign (UDH)	3	6	8	3	-	-	-	-	-	-	-	-	-	-	-	-
Biopsy site	0	0	4	16	-	-	-	-	-	-	-	-	-	-	-	-
Normal (Inter)	4	9	7	0	-	-	-	-	-	-	-	-	-	-	-	-
Normal (Intra)	1	8	11	0	-	-	-	-	-	-	-	-	-	-	-	-
ADH	8	5	4	0	15	0	1	0	2	12	3	0	10	4	2	0
DCIS (low-intermediate)	5	11	4	0	18	0	0	0	3	15	2	0	5	9	2	0
DCIS (high)	4	11	5	0	19	1	0	0	7	12	1	0	11	7	1	0
Infiltrating ductal	1	8	6	5	17	3	0	0	12	8	0	0	17	3	0	0
Radial scar/CSL	5	6	1	0	11	0	0	0	3	6	3	0	8	3	0	0
Total	41	79	59	30	80	4	1	0	27	53	9	0	51	26	5	0
Total for common tissue types	23	41	50	5	80	4	1	0	27	53	9	0	51	26	5	0

## (B) Associations between CTSK and CXCL14 expression levels in stroma or epithelium in various tissue types

Comparisons	CTSK in stroma*			CTSK in epithelium*			CXCL14 in stroma*			CXCL14 in epithelium*		
	Negative	Positive	P	Negative	Positive		Negative	Positive		Negative	Positive	
Overall	120 (58)	89 (42)	—	84 (99)	1 (1)	80 (90)	9 (10)	77 (94)	5 (6)			
1 DCIS (low-intermediate)	16 (80)	4 (20)	1.00	18 (100)	0 (0)	18 (90)	2 (10)	14 (88)	2 (13)			
1 DCIS (high)	15 (75)	5 (25)		20 (100)	0 (0)	19 (95)	1 (5)	18 (95)	1 (5)			
2 DCIS (low-intermediate and high)	31 (78)	9 (23)	0.02	38 (100)	0 (0)	37 (93)	3 (8)	32 (91)	3 (9)			
Infiltrating ductal	9 (45)	11 (55)		20 (100)	0 (0)	20 (100)	0 (0)	20 (100)	0 (0)			
3 DCIS (low-intermediate and high)	31 (78)	9 (23)	1.00	38 (100)	0 (0)	37 (93)	3 (8)	32 (91)	3 (9)			
ADH	13 (76)	4 (24)		15 (94)	1 (6)	14 (82)	3 (18)	14 (88)	2 (13)			
4 Benign (NP)	13 (65)	7 (35)	0.07									
Benign (SA)	12 (60)	8 (40)										
Benign (UDH)	9 (45)	11 (55)										
Radial scar/CSL	11 (92)	1 (8)										
5 Benign, radial scar/CSL	45 (63)	27 (38)	0.55									
Normal (Inter and Intra)	22 (55)	18 (45)										
6 Biopsy site	0 (0)	20 (100)	<0.00001									
Normal (Inter and Intra)	22 (55)	18 (45)										
7 Biopsy site	0 (0)	20 (100)	<0.0001									
DCIS, infiltrating ductal	40 (17)	20 (50)										

## (C) CTSK expression levels in stroma between intralobular and interlobular tissue samples

Gene	Comparison	Intralobular > interlobular	Intralobular < interlobular	P
CTSK in stroma	Intralobular vs interlobular	7 (78)	2 (22)	0.18

## (D) CTSK or CXCL14 expression levels in stroma and in epithelium

Gene	Comparison	Stroma > epithelium	Stroma < epithelium	P
CTSK	Stroma vs epithelium	62 (98)	1 (2)	<0.0001
CXCL14	Stroma vs epithelium	28 (90)	3 (10)	<0.0001

NOTE: (A) Tissue types with all the four expression levels analyzed, including ADH, DCIS (low-intermediate), DCIS (high), infiltrating ductal, and radial scar/CSL. (B) P values in bold were significant after correction for multiple comparisons. Tissue specimens with different histology obtained from the same patient were considered independent results for statistical purposes. Three patients each contributed both DCIS (low-intermediate) and infiltrating ductal carcinoma, DCIS (low-intermediate) and ADH, and benign (SA) and benign (UDH), DCIS (low-intermediate), and biopsy site tissue samples. Six patients contributed both benign (NP) and benign (UDH) tissue samples; two patients contributed all three types of benign tissue samples, including NP, SA, and UDH; one patient contributed both benign (SA) and benign (NP), benign (NP), benign (UDH), and radial scar/CSL tissue samples. (C) All the percentages in the table are calculated based on discrepancy pairs. (D) All the percentages in the table are calculated based on discrepancy pairs. Only tissue samples with expression levels both in stroma and in epithelium available for a given gene were included.

Abbreviation: CSL, complex sclerotic lesions.

\* Values expressed as n (%).

and CXCL14 was scored on a scale of +, ++, and +++. The highest score (of the three or four replicates) was used for statistical analysis and staining was considered to be positive if the highest score was ++ or +++ and considered to be negative if the highest score was - or +. The only exception was CXCL14 expression in the Korean data set, whereas any level of positivity (+, ++, and +++) was considered positive due to the low number (four cases) of samples with ++ and +++; scores.

Breast cancer cell lines were obtained from the American Type Culture Collection; SUM series of breast cancer cell lines and the MCF10ADACIS.com cells (referred to as MCFDCIS) were generous gifts of Dr. Steve Ether (University of Michigan) and Dr. Fred Miller (Karmanos Cancer Institute), respectively. All cell lines were grown in medium recommended by the provider. Fresh, frozen, or formalin-fixed, paraffin-embedded tumor specimens were obtained from multiple sources: the Brigham and Women's Hospital, BIDMC, and UMCC. Primary stromal fibroblast cultures were established and maintained as described (5). All human tissue was collected using protocols approved by the institutional review boards. Samples with clinical follow up data (UMCC cohort) were collected with informed consent.

**RNA isolation and Northern blots.** Total RNA was prepared using a guanidinium cesium chloride method (4). Northern blot analysis was done as described (27).

**Immunohistochemical and immunoblot analysis.** Immunohistochemical analyses of CTSK expression was done essentially as described (28) using monoclonal anti-CTSK antibody clone CK4 (Vision Biosystems), whereas staining for CXCL14 was done following a protocol provided by Dr. Galina Shurin (University of Pittsburgh; ref. 20). Western blots were done using cell lysates and antibodies to CTSK (clone CK4), CISL (clone 13C2), CTSB (clone CB121), and CTSF (clone CT12) all from Vision Biosystems. The expression levels were analyzed blindly and independently by breast pathologists and classified into -, +, ++, and +++ following a previously validated scoring schema (26).

**Cell proliferation, migration, and invasion assays.** To determine the effect of cathepsin inhibitors on two-dimensional cell growth, we plated 2,000 cells per well in a 48-well plate and grew them in their regular growth medium (control) or with different concentrations of the inhibitors. Cells were counted (two wells per time point) on days 1, 3, and 6 after plating. Proliferation assays in three-dimensional culture were done essentially the same way. To determine whether inhibition of cathepsin activity influences cell migration and invasion, we tested cells using BioCoat Matrigel invasion chambers (BD Biosciences) essentially as described (29). For invasion assays, we plated  $2.5 \times 10^3$  cells per well and assayed 36 h later, whereas, for migration assays, we used  $2.5 \times 10^4$  cells per well in BioCoat plates without Matrigel and determined cell numbers 12 h later. The inhibitors were added at different concentrations (0.33–20  $\mu$ M/L) in both top and bottom wells of the assay at the time the cells were added. All of the above-described experiments were repeated at least three times. CTSB inhibitor IV, CISL inhibitor, CTSK inhibitor I were purchased from Calbiochem, whereas other CTSK inhibitors were provided by Dr. Johann Zimmermann (Novartis Pharma).

**Statistical analyses.** The BIDMC tissue samples were collected from breast cancer patients and patients who underwent breast reduction surgery. Some cancer patients had multiple lesions and also multiple blocks of the same lesion. Tissue samples of different lesions from the same patient were treated as independent samples in the analysis. For patients with more than one tissue sample of the same histology, one of the samples was randomly selected for analysis. Each of the patients with a normal interlobular tissue specimen also had a normal intralobular tissue specimen; thus, the comparison of CTSK expression levels in these two tissue types used a paired test (McNemar) to assess whether one of the two types of discrepancy was significantly more common than the other. McNemar's test was also used to compare CTSK expression levels in the stroma and epithelium (when available in

**Table 2. CTSK expression in invasive breast carcinomas**

	-	+	++	+++	Total
CTSK in stroma	31 (24)	49 (38)	41 (32)	9 (7)	130 (100)
CTSK in epithelium	25 (19)	45 (35)	46 (35)	14 (11)	130 (100)

NOTE: Overall distribution of CTSK expression levels in stroma and in epithelium. Values in table expressed as *n* (%).

the same patient) and to compare CXCL14 expression levels in the stroma and epithelium (when available in the same patient). Few patients in the BIDMC data set had specimens from two or more of the other tissue types (legend of Table 1 show the numbers of patients who had each relevant combination), so the comparison of expression levels in these tissue types was unpaired, used Fisher exact tests, and was based on treating results from different tissue types in a single patient as independent. The distribution of the expression levels and the available data on CTSK and CXCL14 expression levels in stroma and epithelium for each tissue type are summarized in Table 1A and Supplementary Table S2. Except for CTSK expression in stroma, there were very few tumor samples with expression levels classified as ++ or +++; (as shown in Table 1A) and only these two categories were defined as positive. Therefore, no comparisons between tissue types were done for CTSK expression levels in epithelium, CXCL14 expression levels in stroma, or CXCL14 expression in epithelium. The Holmes correction was used to adjust for multiple comparisons of CTSK expression in stroma for various tissue types in the BIDMC data set.

The Korean data set (merged from two separate commercial sources) consisted of 217 patients, of which 146 were included in the analysis. Reasons for exclusion included male patients (4), T<sub>4</sub> stage (7), lymph node metastasis (10), normal tissues (23), papillary carcinoma (10), DCIS (8), phyllodes tumors (6), postexcisional biopsy (1), and lack of gene expression levels (2). Not all patients had both CTSK and CXCL14 measured, and not all patients had the same prognostic factors recorded, so the sample sizes for the comparisons varied. Some patients had two replicate scores for a given gene expression level, and the higher score was used for analysis. Fisher's exact test and a step-up logistic regression (using the likelihood ratio test) were used to assess the relationships between CTSK or CXCL14 expression levels and tumor and patient characteristics. As with the BIDMC data, CTSK expression levels were dichotomized for analysis as negative (including - and +) and positive (including ++ and +++). There were no tumor samples with +++ CXCL14 and very few tumor samples with CXCL14 in the ++ category; therefore, CXCL14 expression levels were dichotomized as positive (including +, ++, and +++) or negative for analysis. There were no corrections for multiple comparisons in the analysis of the Korean data set.


In the UMCC data set, a total of 141 patients had both CTSK expression levels and clinical data available. Among the 141 patients, 11 patients were excluded from the main analysis due to the following reasons: date of diagnosis was >1 month after date of surgery (4), inflammatory cancer (1), M<sub>1</sub> stage (3), and T<sub>4</sub> stage (3). Table 2 shows the overall distribution of CTSK expression levels in stroma and epithelium. As with the BIDMC data, the CTSK expression levels were dichotomized as negative (including - and +) and positive (including ++ and +++). To assess the association of tumor and patient characteristics on CTSK expression levels, Fisher's exact test and a step-up logistic regression were used. For the analyses of RFS, the Kaplan-Meier curve estimate and a step-up Cox proportional hazards regression model were used. For both models, variable selection was based on the likelihood ratio test. There were no corrections for multiple comparisons in the analysis of the UMCC data set.

## Results and Discussion

**Expression of cathepsins, cystatins, and CXCL14 in normal and neoplastic human breast tissue.** Based on our serial analysis of gene expression of different cell types composing normal breast tissue and *in situ* and invasive breast carcinomas, we found that several cathepsins (CTSB, CTSF, CTSK, and CTSL) and CXCL14 chemokine were dramatically up-regulated in DCIS myoepithelial cells compared with normal myoepithelium (4). In addition, myofibroblasts of both *in situ* and invasive carcinomas expressed several cathepsins at very high levels, whereas tumor epithelial cells were largely negative for most genes with the exception of CTSB, which was highly expressed in most cell types in tumors (Fig. 1A; Table 3A). Interestingly, among epithelial cells, only the CD44<sup>+</sup> stem cell-like cells had significant CTSK and CXCL14 expression correlating with our prior data implying a role for these cells in invasion and angiogenesis (30). Besides cathepsins, several angiogenesis inhibitors including cystatin C were also up-regulated in DCIS-

associated myoepithelial cells and myofibroblasts raising the possibility that alterations in cysteine protease balance in epithelial and various stromal cells composing the microenvironment may contribute to breast tumor progression by promoting invasion.

To test this hypothesis, we had to identify suitable models of human breast cancer. Thus, we first analyzed the expression of CTISB, CTISF, CTISK, and CTISI in human breast cancer cell lines, freshly isolated (uncultured) organoids, and primary cultured fibroblasts derived from normal breast tissue and breast carcinomas (Fig. 1B and C; Supplementary Table S1). Correlating with our serial analysis of gene expression data in primary human breast tissue samples, CTISB and CTISI were highly expressed in most breast cancer cell lines, whereas no significant expression of CTISF and CTISK were detected in most of the cell lines tested (Fig. 1B). We also analyzed several breast cell lines and primary cultured breast stromal fibroblasts by immunoblot to correlate mRNA levels with protein levels and activation status. Correlating with the Northern blot data, CTISF



**Fig. 1.** Expression of CXG14, cathepsin, and cystatins in human breast tissue. *A*, Dendrogram depicting clustering of the indicated sense analysis of gene expression libraries based on the expression of the genes listed. *Bleu rectangle*, high expression of CTSK and CXG14 in DCIS-associated myoepithelial cells, myofibroblasts, and fibroblasts and in a subset of breast epithelial cells with stem-like phenotypes. *B*, Northern blot analysis of CTSB, CTSE, CTSK, and CTSL RNA levels in the indicated breast cancer cell lines and normal breast organs. *C*, Immunoblot analysis of CTSF, CTSL, and CTSK expression in the indicated breast cancer cell lines, normal organs, and primary cultured normal breast (PB) and breast tumor (PBt) fibroblasts. CTSK expression is only detected in primary cultured breast stromal fibroblasts. The 37- and 25-kDa bands on the CTSK blot correspond to pro- and mature proteins, respectively, whereas in the case of CTSF and CTSL, only mature propeptides were detected on the gel. *D*, Immunohistochemical analysis of CTSK expression in human DCIS and in xenografts derived from the MCFDCS cell line. High CTSK expression is detected in stromal myofibroblasts in both cases.

**Table 3.** Cathepsins and their inhibitors

(A) Expression of cathepsins, their inhibitors, and CXCL14 in various cell types isolated from normal and neoplastic breast tissue																
UniGene	Symbol	Name	Location	Tag	EPI-N1	EPI-N2	EPI-DCIS2	EPI-DCIS3	EPI-DCIS6	EPI-DCIS7	EPI-IDC8	EPI-IDC9	EPI-IDC7	CD24-N1	CD24-N2	CD24-N4
Hs.123114	CS T1	Cystatin SN	20p11.21	GTACACACCC	0	0	0	0	0	1	0	0	0	0	0	0
Hs.669305	CS T2	Cystatin SA	20p11.21	GTACACACAC	0	0	0	0	0	2	0	0	0	0	0	0
Hs.304682	CS T3	Cystatin C	20p11.21	TGCGCTGCACC	24	13	93	13	3	51	31	31	9	1	4	7
Hs.121489	CST5	Cystatin D	20p11.21	CGCGCTGCACC	0	0	0	0	0	0	0	0	0	0	0	0
Hs.139389	CST6	Cystatin E/M	11q13	GTGGAGGGCA	0	0	1	0	2	0	0	10	1	0	0	0
Hs.143212	CST7	Cystatin F (leukocystatin)	20p11.21	TAGGCCGCTC	0	0	0	0	0	1	0	0	0	0	0	0
Hs.558623	CST9	Cystatin 9 (testatin)	20p11.21	CTGGCCCCCTC	0	0	0	1	0	1	0	0	0	0	0	0
Hs.121554	CST9L	Cystatin 9-like	20p11.21	TAGTGTAGAT	0	0	1	0	0	0	0	1	0	0	0	0
Hs.518198	CSTA	Cystatin A (stefin A)	3q21	ATCCCTGCTG	0	2	1	0	0	0	0	0	0	0	0	0
Hs.695	CSTB	Cystatin B (stefin B)	21q22.3	ATGAGCTGAC	5	4	4	0	2	12	8	12	2	1	1	16
Hs.352134	CSTL1	Cystatin-like 1	20p11.21	TGGGAGGAAA	0	0	0	0	0	0	0	0	0	0	0	0
Hs.652282	CTSA	Cathepsin A	20q13.1	TCTCCCGCT	0	0	2	1	4	3	1	6	1	0	4	3
Hs.520896	CTSB	Cathepsin B	8p22	TGGGGAGGCC	10	5	6	7	5	17	5	19	8	11	7	16
Hs.128065	CTSC	Cathepsin C	11q14.1-q14.3	CTATATTTTT	0	0	0	0	0	1	1	0	0	0	0	0
Hs.654447	CTSD	Cathepsin D	11p15.5	GACATCGCCG	0	0	0	0	1	1	0	0	1	1	0	0
Hs.644082	CTSE	Cathepsin E	1q31	AGAAATACACA	0	0	0	1	1	0	0	0	0	0	0	2
Hs.11590	CTSF	Cathepsin F	11q13	TCCAGGAAC	7	1	27	3	5	1	5	3	3	4	0	0
Hs.421724	CTSG	Cathepsin G	14q11.2	AGGAGGGGAA	0	1	0	0	0	0	0	1	0	0	0	0
Hs.148641	CTSH	Cathepsin H	15q24-q25	GACCACGAAT	1	1	4	1	0	5	1	0	0	0	3	0
Hs.632466	CTSK	Cathepsin K	1q21	ATAAAAAGAA	0	0	1	0	1	1	1	1	1	0	0	0
Hs.418123	CTSL1	Cathepsin L1	9q21-q22	GGAGGAATTTC	1	1	2	1	1	0	4	1	2	1	1	4
Hs.660866	CTSL2	Cathepsin L2	9q22.2	TCTGGGGAAA	1	0	0	0	0	0	0	0	0	1	0	4
Hs.75262	CTSO	Cathepsin O	4q31-q32	AAATGCACTG	0	1	1	0	0	0	0	1	1	0	0	0
Hs.181301	CTSS	Cathepsin S	1q21	CTTTAAAAAA	0	1	0	1	1	3	3	0	2	0	0	0
Hs.252549	CTSZ	Cathepsin Z	20q13	GCTCTGCC	7	5	2	0	2	1	2	0	3	1	3	3
Hs.483444	CXCL14	Chemokine (C-X-C motif)	5q31	CAGGTTTCA	0	1	0	7	7	1	6	1	1	0	1	1
ligand 14																

**(B) Summary of results of growth inhibition assays with various cathepsin inhibitors**

Cell line	CTSB inhibitor	CTS1 inhibitor	CTSK inhibitor	CTS1 inhibitor (A and B)
BT-549	Inhibition of growth at 20 μmol/L	No response		ND
MDA-MB-231	Inhibition of growth at 20 μmol/L	No response		ND
MDA-MB-435	Inhibition of growth at 20 μmol/L	Morphologic changes at 10 μmol/L		ND
MCF10DCIS	Inhibition of growth at 20 μmol/L	No response		No response
MCF10DCIS+stroma	Inhibition of growth at 20 μmol/L	No response		No response

NOTE: (A) Gene names and symbols, serial analysis of gene expression tag numbers (normalized to 50,000) and sequence, UniGene IDs, and chromosomal location are indicated. CD24, CD44, and MUC1 refer to cells purified using these cell surface markers. (B) Cells, inhibitor used, concentration, and results are indicated.

Abbreviations: N, normal; D, DCIS; I, invasive; EPI, epithelial cells; MYOPEI, myoepithelial cells; MYOFIB, myofibroblasts; STR, stromal fibroblasts; ND, not determined.

and CTS1 were expressed in most cells, whereas high CTSK protein levels were only detected in primary cultured fibroblasts derived from normal and neoplastic breast tissue (Fig. 1C). The restricted expression of CTSK to breast stromal fibroblasts was also confirmed by immunohistochemical analysis of human primary DCIS and xenografts derived from the MCF10DCIS cell line (Fig. 1D; ref. 31).

**Effect of cathepsin inhibitors on cell proliferation, survival, migration, and invasion.** To begin dissecting the functional relevance of high cathepsin expression in breast tumor epithelial and stromal cells, we analyzed the effect of several cathepsin inhibitors on the proliferation, migration, and invasion of breast cancer cell lines selected based on their expression pattern of the various cathepsins. Proliferation

assays were done in both two-dimensional and three-dimensional conditions; in the latter case, the cells were embedded in Matrigel. We found that high concentration (20 μmol/L) of cathepsin B inhibitor inhibited the growth of all cell lines tested, whereas lower doses had no discernable effect. CTS1 inhibition did not have an effect on cell proliferation at any concentration tested, but at 10 μmol/L it appeared to alter the morphology of MDA-MB-435 cells growing in Matrigel (Fig. 2A) potentially by reducing the invasiveness of the cells. To test this hypothesis, we analyzed the effect of cathepsin B and I, inhibitors on the migration and invasion of MDA-MB-435 cells at a concentration that did not affect cellular proliferation in three-dimensional cultures. Neither inhibitor had significant effect on cell migration, but both very potently

**Table 3.** Cathepsins and their inhibitors (Cont'd)

(A) Expression of cathepsins, their inhibitors, and CXCL14 in various cell types isolated from normal and neoplastic breast tissue

CD24-PE2	CD24-IDC26	CD24-IDC26	MUC1-N2	MUC1-N3	MUC1-N4	CD44-N1	CD44-N4	CD44-IDC29	CD44-IDC28	CD44-PE2	CD44-AC3	MYOEP1-N1	MYOEP1-N2	MYOEP1-N4	MYOEP1-DCIS6	MYOEP1-DCIS7	MYOEP1-N-IDC7	MYOFPB-IDC8	MYOFPB-IDC9	MYOFPB-IDC7	STR-N1	STR-N-IDC8	STR-IDC7	STR-DCIS6	
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	4	2	0	1	0	0	2	3	0	
32	43	20	26	17	19	18	24	41	58	72	45	3	13	3	30	53	39	54	35	29	21	34	41	50	
1	0	0	0	0	0	0	1	0	1	0	1	0	0	0	0	0	1	2	0	0	0	0	0	0	
3	5	0	0	0	1	1	1	0	2	0	2	1	1	1	2	2	0	0	0	0	0	0	0	0	
0	0	0	0	0	0	1	5	0	0	0	2	0	0	0	0	0	1	0	0	0	2	0	0	0	
0	0	3	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
0	0	0	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
10	7	3	6	10	5	3	4	15	8	14	10	1	4	5	3	4	3	4	5	6	1	7	3	2	
0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	
2	4	1	2	0	1	0	4	1	9	9	3	0	0	0	1	3	1	2	6	8	1	1	0	0	
22	8	26	15	39	19	12	24	26	63	510	99	1	5	2	14	6	25	38	58	57	4	14	22	23	
0	0	0	1	0	0	2	1	2	1	11	0	0	1	2	0	0	6	2	2	0	0	2	3	2	
5	2	0	1	0	2	1	0	0	4	12	1	0	0	0	1	0	1	2	1	0	0	0	1	0	
0	0	0	1	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	
2	9	3	2	5	3	4	0	5	3	1	8	0	1	0	25	41	10	12	6	7	59	2	4	9	
0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	2	0	0	0	
1	0	1	0	0	1	0	0	1	0	3	0	0	0	0	1	4	4	7	0	3	0	6	1	10	
0	0	1	0	3	2	2	13	8	13	0	0	0	1	1	47	16	23	49	67	21	34	5	16	23	
17	3	1	2	7	16	76	112	39	48	186	32	0	4	23	13	14	10	10	18	12	9	23	8	9	0
0	0	0	0	0	1	0	0	0	0	0	6	4	1	0	0	1	0	1	0	0	0	0	0	0	
1	0	0	1	0	0	1	2	1	0	0	1	2	0	0	0	1	1	2	5	3	1	1	3	3	
0	0	0	2	0	0	1	1	0	0	0	0	1	0	2	1	1	0	3	0	0	2	0	1	1	
0	1	0	1	0	0	2	1	3	2	6	0	1	4	2	1	3	3	5	6	5	4	0	3	6	
23	1	3	0	0	1	3	25	13	51	3	0	9	14	11	75	89	53	71	27	22	20	16	20	48	

inhibited invasion through Matrigel (Fig. 2B), suggesting that up-regulation of cathepsin B and L expression in breast tumor cells may promote their ability to degrade extracellular matrix and enhance their invasive and metastatic behavior.

CTSK was not expressed in any of the breast cancer cell lines we tested, but it was highly expressed in primary cultured breast stromal fibroblasts (Fig. 1B) similar to what we observed in the majority of primary breast tumors. This expression pattern raised the hypothesis that CTSK may influence tumor epithelial cell behavior via paracrine interactions. To test this hypothesis, we cocultured CTSK-expressing breast stromal fibroblasts with MCFDCIS cells (31, 32), a noninvasive breast cancer cell line in Matrigel. Coculturing MCFDCIS cells with breast stromal fibroblasts dramatically altered the morphology of the cells (Fig. 2C). MCFDCIS cells embedded in Matrigel formed small round acini, and only at later time points (after 8 days in culture), we observed occasional branching. Embedding MCFDCIS cells together with breast stromal fibroblasts resulted in the outgrowth of extensively branched structures (Fig. 2C). This observation suggested that fibroblasts may enhance the invasiveness of MCFDCIS cells or alter the morphology of the forming structures and CTSK expressed in the fibroblasts may play a role in this process.

To test the hypothesis that fibroblasts enhance epithelial cell invasion, we did migration and invasion assays using MCFDCIS cells and breast fibroblasts. We infected the MCFDCIS cells with an adenovirus expressing green fluorescence protein for these assays to be able to differentiate between the two cell types.

Coculture with breast fibroblasts significantly enhanced the invasion of MCFDCIS cells but had no significant effects on their migration (Fig. 2D). Addition of CTSK inhibitors had no effect on the migration of the cells but dramatically reduced the invasion promoting effect of breast fibroblasts on MCFDCIS cells (Fig. 2D and E). The proliferation of MCFDCIS cells was not affected by the CTSK inhibitors used at a concentration that inhibited invasion in cocultures (Supplementary Fig. S1).


In summary, these results implied that stromal CTSK expression may play a role in breast tumor progression by promoting invasion, and as a consequence of this, it may influence the clinical outcome of breast cancer patients.

**CTSK and CXCL14 expression in normal, benign, and malignant breast lesions.** To determine the expression of CTSK in breast tumor progression, we analyzed its expression in normal breast (interlobular and intralobular stroma), in various benign lesions including usual ductal hyperplasia (UDH), sclerosing adenosis (SA), nonproliferative disease (NP), radial scar, biopsy sites, and in ADH, DCIS, and invasive and metastatic breast carcinomas from the BIDMC data set (Supplementary Table S2). We also analyzed CXCL14 expression in some of the tissue samples, including ADH, DCIS, radial scar, and infiltrating ductal, because our serial analysis of gene expression data indicated that CXCL14 and CTSK are coexpressed in the same tumor and cell types (Fig. 1A; Table 1A). The associations between CTSK expression levels in stroma and tissue types are summarized in Table 1B; representative images of immunohistochemical results are in Fig. 3A and B


(No tests were done for CTSK expression in epithelium or CXCL14 expression in either stroma or epithelium because of the paucity of positive levels for these cases).

No significant difference was found in stromal CTSK levels between high-grade and low-to-intermediate-grade DCIS. Infiltrating ductal carcinoma samples were more likely to have positive CTSK expression levels in the stroma than DCIS samples, but this was only marginally significant ( $P = 0.02$ ; the cutoff after correcting for multiple comparisons would be 0.0071), although significant difference was found when expression levels were categorized into four categories ( $P = 0.004$ ). No significant difference was found in CTSK positivity between DCIS and ADH tumor samples (Table 1B). Among benign lesions, UDH had the highest percentage of

positive CTSK expression levels, whereas radial scar had the lowest percentage, but the percentages of positivity among the four benign lesions were not statistically significantly different ( $P = 0.07$ ). Comparison of all four types of benign tissue samples with normal tissues (including interlobular and intralobular stroma) was not significant ( $P = 0.55$ ). In contrast, CTSK expression levels in biopsy site tissue samples were significantly ( $P < 0.0001$ ) more likely to be positive than in normal tissue samples (including interlobular stroma and intralobular stroma). CTSK expression was always positive in biopsy sites, whereas 55% of normal tissue samples were negative. Similarly, CTSK was significantly ( $P < 0.0001$ ) more likely to be positive in tissue from biopsy sites compared with DCIS and invasive breast tumors. CTSK expression in biopsy sites was



**Fig. 2.** Effect of cathepsin inhibitors on breast cancer cells. **A**, three-dimensional growth of MDA-MB-435 cells in Matrigel in the presence and absence of CTSB or CTSL inhibitors used at the indicated concentrations. MDA-MB-435 cancer cells grow in a highly invasive, branching pattern in Matrigel. Addition of CTSB inhibitor at 2 μM concentration did not influence invasion, whereas at 20 μM it dramatically inhibits invasion. CTSL inhibitor at 10 μM (Lysosomal inhibitor) the branching growth of the cells. **B**, representative summary of migration and invasion assays determined in the presence and absence of CTSB or CTSL inhibitor used at the indicated concentrations. Y-axis, number of cells migrating or invading through the membrane/well. Numbers, mean ± SD. The experiment was repeated three times with essentially identical results. **C**, growth of MCFDCIS cells in Matrigel alone or cocultured with breast stromal fibroblasts (+PBS). Image was acquired on day 8 of the culture. The cells alone form spheroid-like structures with occasional branching, whereas coculturing with fibroblasts dramatically enhanced branching growth. **D**, migration and invasion of green fluorescence protein–positive MCFDCIS cells alone or cocultured with fibroblasts (+PBS) in the presence of CTSK inhibitors used at the indicated concentrations. Representative experiment done in triplicate. *Left*, actual images of the cells; *right*, quantitative summary of the invasion assays shown in the photos. Y-axis, number of cells invading through the membrane/well. *Numbers*, representative experiment done in triplicate; *Bars*, SD. The experiment was repeated three times with essentially the same results.



**Fig. 3.** Immunohistochemical analyses of CTSK and CXCL14 expression in human breast tissue samples. **A**, CTSK expression in normal breast and in various benign and malignant breast lesions. **B**, CXCL14 expression in DCIS and invasive breast carcinoma. In the majority of DCIS, only stromal and myoepithelial staining was observed, but in some tumors the epithelial cells expressed high levels of CXCL14. **C**, CTSK expression in primary invasive tumor and matched distant metastases.

always positive, whereas only 33% of DCIS and infiltrating ductal carcinomas were positive. The expression of CTSK in the stroma of biopsy sites indicates the recruitment of CTSK+ myofibroblasts to the tissue injury and a potential role for CTSK in tissue remodeling and wound healing via modulation of extracellular matrix degradation and angiogenesis.

Next, we compared CTSK expression levels (divided into the four categories: -, +, ++, and +++) between interlobular stroma and intralobular stroma within tissue samples from the same patient (Table 1C). Nine patients had discordant expression of CTSK between interlobular and intralobular stroma. Among these 9 cases, there were 7 (78%) patients with higher CTSK expression levels in the intralobular stroma and 2 (22%) patients with higher CTSK expression levels in the interlobular stroma, but this difference was not statistically significant ( $P = 0.18$ ). We also tested if the expression levels of CTSK and CXCL14 (each divided into four categories) were different between stromal and epithelial cells within the same tissue sample to determine if their expression in the different cell

types is coregulated. Among all tissue specimens analyzed, 85 samples had CTSK expression levels determined both in the stroma and in the epithelium. Among the 63 discrepant pairs, 62 (98%) had significantly ( $P < 0.0001$ ) higher CTSK expression levels in the stroma than in the epithelium (Table 1D). Eighty-two tissue samples had CXCL14 expression levels both in the stroma and in the epithelium. Among the 31 discrepant pairs, 28 (90%) had higher CXCL14 expression levels in the stroma than in the epithelium, and this difference was also highly significant ( $P < 0.0001$ ).

Finally, we compared the expression of CTSK in matched primary tumors and distant metastases. Interestingly, high CTSK expression was observed in the stroma of the primary tumor and bone metastasis, whereas liver metastases were essentially negative for CTSK expression (Fig. 3B). These results are consistent with the proposed role of CTSK in osteolytic breast cancer bone metastases (13).

In summary, CTSK expression in the stroma was frequently detected (at a + or ++ level) in various specimens of normal

breast tissue and benign and malignant breast lesions (42% overall). CXCL14 expression in the stroma was seldom detected at this level (10% of specimens). The majority of CTSK and CXCL14-positive stromal cells were myofibroblasts, whereas a subset of DCIS-associated myoepithelial cells and leukocytes showed variable expression. Epithelial CTSK expression was rarely detected in invasive ductal carcinomas, whereas CXCL14 was expressed in the epithelial cells of a subset of DCIS and ADH tumors.

**Associations between CTSK or CXCL14 expression and patient and tumor characteristics and clinical outcome.** To determine if the expression of CTSK or CXCL14 correlates with clinical outcome, we did immunohistochemical analysis for invasive breast tumors with clinical follow-up data in the UMCC and the Korea data sets. Among the 146 patients included in the analysis for the Korea data set, 111 and 65 had CTSK and CXCL14 expression levels analyzed, respectively. The CTSK expression levels in stroma were dichotomized as being negative (- or +) or positive (++ or +++). When using the Fisher's exact test to assess the relationships between CTSK expression levels and tumor and patient characteristics, T stage ( $P = 0.02$ ) and estrogen receptor (ER) status ( $P = 0.05$ ) were significantly associated with CTSK positivity (Supplementary Table S3). Patients with T<sub>1</sub> stage tumors were more likely to be negative for CTSK than patients with T<sub>2</sub>/T<sub>3</sub> stage, whereas ER-negative tumors were more likely to be positive for CTSK than were ER-positive tumors. In the Korean data set, 18% of the 22 patients with T<sub>1</sub> tumors had positive CTSK in stroma versus 52% of the 87 patients with T<sub>2</sub> or T<sub>3</sub> tumors. In the UMCC data set, 37% of the 70 patients with T<sub>1</sub> tumors had positive CTSK in stroma versus 41% in the 59 patients with T<sub>2</sub> or T<sub>3</sub> tumors. In the Korean data set, 37% of the 60 ER-positive patients had positive CTSK in stroma versus 57% of the 51 ER-negative and unknown patients. In the UMCC data set, 38% of the 81 ER-positive patients had positive CTSK in stroma versus 34% of the 44 ER-negative patients. The differences between the two cohorts analyzed with respect to CTSK expression in tumor stage and hormone receptor status could potentially be due to differences in ethnicity and/or age. The evaluation of larger independent data sets would be necessary to determine if either of these variables could influence CTSK expression.

In the step-up logistic models for CTSK expression levels, T<sub>1</sub> stage was the most significant covariate to add to the model ( $P = 0.002$ , after adjusting for T stage unknown). With T<sub>1</sub> stage in the model, no other variable (including ER status) added significantly to this model. When including all the possible covariates in the logistic model, T<sub>1</sub> was still significantly associated with CTSK expression levels ( $P = 0.01$ ), but ER status was not.

The CXCL14 levels were dichotomized as completely negative (-) versus positive at any level (+, ++, or +++). There was no significant association between this categorization of CXCL14 expression levels and tumor and patient characteristics using Fisher's exact test. The variable closest to significant was overall tumor stage; patients with stage III breast cancer were less likely to be completely negative for CXCL14 expression than stage I/II breast cancer patients ( $P = 0.13$ ).

In the UMCC data set, there were 38% and 46% of patients with positive CTSK expression levels (defined as ++ or +++) in the stroma and in the epithelium, respectively. There was no significant association between CTSK expression and patient

characteristics using Fisher's exact test (Supplementary Table S4). In the step-up logistic models for CTSK expression levels in the stroma, N stage II/III was the covariate closest to significant ( $P = 0.07$ , after adjusting for N stage unknown). Patients with N stage II/III were less likely to have CTSK-positive stroma. As for CTSK expression levels in the epithelium, the covariate closest to significant was lobular or mixed lobular and ductal histology ( $P = 0.09$ ). Patients with lobular or mixed lobular and ductal histology were less likely to have positive CTSK in epithelium than were patients with pure ductal or other histology. However, none of the above was statistically significant.

To determine if CTSK expression in the stroma or in the epithelium influences clinical outcome, we analyzed the association between CTSK levels and RFS in the UMCC data set (which had an overall median RFS of 107 months, with 72 RFS events and 55 patients with censored RFS) using a step-up Cox proportional hazards model. The covariates significantly associated with longer RFS, in the order added to the model, were age at diagnosis 48 to 59 years (the second quartile), disease stage I or II (versus III), prior radiotherapy, and progesterone receptor positive (see Supplementary Table S5). Neither CTSK expression level in stroma nor CTSK expression level in epithelium was significantly associated with RFS, although there were enough failures to have ~80% power to detect a hazard ratio of ~2.2 for each of these variables (Supplementary Table S6).

We also analyzed the relationship between overall survival (defined as time from diagnosis to death) and CTSK expression levels in the UMCC data set by using the log-rank test. The median overall survival was 122 months among the 127 patients with survival data available. No significant association was found ( $P = 0.51$  and 0.75 for dichotomized CTSK in stroma and epithelium, respectively). Of the 127 patients with survival data available, 73 had died; 34 died of breast cancer, whereas 39 died of other causes. More than 50% of the deaths were due to reasons other than breast cancer.

**Conclusions.** The results of our study show that stromal CTSK expression promotes breast tumor epithelial cell invasion *in vitro*. In human breast tissues, stromal CTSK expression is elevated in association with invasive ductal carcinomas when compared with DCIS, underscoring the role of CTSK as a paracrine tumor progression factor. Furthermore, CTSK-positive stroma was associated with a higher tumor stage and a negative ER status, two features associated with worse clinical outcome. Based on these data, we hypothesize that CTSK-positive stromal fibroblasts may play a role in breast tumor progression by promoting extracellular matrix degradation and angiogenesis and by increasing the invasiveness of neighboring tumor epithelial cells. Thus, CTSK inhibitors may offer a novel therapeutic option to decrease breast tumor progression.

### Disclosure of Potential Conflicts of Interest

K. Ployak has received a commercial research grant from Novartis and is a Novartis consultant.

### Acknowledgments

We thank Diana Calogrias for help with the acquisition of human tissue samples, Beatrix Faldstiel for assistance in the immunohistochemical scoring and recording, and Dr. Johann Zimmermann (Novartis) for providing CTSK inhibitors and for recommendation of antibodies.

## References

- Biegel MJ, Ritzi A, Mian IS. Tissue architecture: the ultimate regulator of breast epithelial function. *Curr Opin Cell Biol* 2003;15:753–62.
- Wennerberg R, Mihach E. Eighteenth Annual Pecociller Symposium: tumor microenvironment and heterotypic interactions. *Cancer Res* 2006;66:11560–3.
- Tisay TD. Stromal cells can contribute oncogenic signals. *Semin Cancer Biol* 2003;14:97–104.
- Allison M, Basourkhan R, Cai L, et al. Molecular characterization of the tumor microenvironment in breast cancer. *Cancer Cell* 2004;6:17–32.
- Hu M, Yao J, Cai L, et al. Distinct epigenetic changes in the stromal cells of breast cancers. *Nat Genet* 2005; 37:899–905.
- Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. *N Engl J Med* 1989;316:1650–9.
- Jedrzejko C, Sloane BF. Cysteine cathepsins in human cancer. *Biol Chem* 2004;385:1017–27.
- Gocheva V, Zeng W, Ke D, et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. *Genes Dev* 2006;20:543–66.
- Abrahamson M, Alvarez-Fernandez M, Nathanson CM. Cystatins. *Biochem Soc Symp* 2002;70:179–99.
- Joyce JA, Baruch A, Chéhadé K, et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. *Cancer Cell* 2004;5:443–53.
- Bell-McGinn KM, Garfall AL, Bogyo M, Hanahan D, Joyce JA. Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. *Cancer Res* 2007;67: 7378–85.
- Safri P, Hunziker E, Wehmeyer O, et al. Impaired osteoclast bone resorption leads to osteopetrosis in cathepsin K-deficient mice. *Proc Natl Acad Sci U S A* 1998;95:13453–8.
- Lo Gall C, Bellahcene A, Bonneyle E, et al. A cathepsin K inhibitor reduces breast cancer induced osteosarcoma and skeletal tumor burden. *Cancer Res* 2007;67: 9894–902.
- Vasileva O, Reinheckel T, Peters C, Turk D, Turk V, Turk B. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. *Curr Pharm Des* 2007;13:387–403.
- Vasileva O, Turk B. Dual contrasting roles of cysteine cathepsins in cancer progression: apoptosis versus tumor invasion. *Biochimie* 2008;90:380–6.
- Littlewood-Evans AJ, Bilbe G, Bowler WB, et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. *Cancer Res* 1997;57:5386–90.
- Fredrick MJ, Henderson Y, Xu X, et al. *In vivo* expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. *Am J Pathol* 2006;160:1937–50.
- Ozawa S, Kato Y, Komori R, Maehata Y, Kubota E, Hata H. BRAK/CXCL14 expression suppresses tumor growth *in vivo* in human oral carcinoma cells. *Biochem Biophys Res Commun* 2006;348:406–12.
- Schwarz RE, Luo J, Isaacs WB, Jarrad DF. Modulation of CXCL14 (BRAK) expression in prostate cancer. *Prostate* 2006;64:67–74.
- Stearns T, Fomin RA, Stamenkovic I, et al. Loss of new lymphocyte CXCL14 in tumor tissue is associated with low infiltration by dendrite cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both *in vitro* and *in vivo*. *J Immunol* 2006;174:5490–8.
- Stearns T, Rasila KK, Robertson MJ, et al. The chemokine CXCL14 (BRAK) stimulates activated NK cell migration: implications for the downregulation of CXCL14 in malignancy. *Exp Hematol* 2006;34: 1101–5.
- Shallenberger TD, Wang M, Gujini M, et al. BRAK/CXCL14 is a potent inhibitor of angiogenesis and a chemoattractant factor for immature dendritic cells. *Cancer Res* 2004;64:8262–70.
- Meuter S, Schauer P, Ross RS, et al. Murine CXCL14 is dispensable for dendrite cell function and localization within peripheral tissues. *Mol Cell Biol* 2007;27: 983–92.
- Nara N, Nakayama Y, Okamoto S, et al. Disruption of CXC motif chemokine ligand-14 in mice ameliorates obesity-induced insulin resistance. *J Biol Chem* 2007; 282:30794–803.
- Takahashi M, Takahashi Y, Takahashi K, et al. CXCL14 enhances insulin-dependent glucose uptake in adipocytes and is related to high fat diet-induced obesity. *Biochem Biophys Res Commun* 2007;364:1037–42.
- Kleer CG, Cao Q, Vararambally S, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. *Proc Natl Acad Sci U S A* 2003;100:11606–11.
- Porter DA, Krop IE, Nisser S, et al. A SAGE (serial analysis of gene expression) view of breast tumor progression. *Cancer Res* 2001;61:5697–702.
- Porter D, Lahti-Domenici J, Kesheviah A, et al. Molecular markers in ductal carcinoma *in situ* of the breast. *Adv Cancer Res* 2003;1:162–75.
- Muller A, Hurmy B, Soto H, et al. Involvement of chemoattractant receptors in breast cancer metastasis. *Nature* 2004;410:50–6.
- Stephens M, Campbell LL, Argani P, et al. Molecular definition of breast tumor heterogeneity. *Cancer Cell* 2007;11:269–73.
- Miller FB, Santini SJ, Tait L, Dawson PJ. MCP-1/CC-1020 can xenograft model of human comedo ductal carcinoma *in situ* [letter]. *J Natl Cancer Inst* 2000;92:1156–6.
- Miller F. Xenograft models of premalignant breast disease. *J Mammary Gland Biol Neoplasia* 2000;6: 379–91.